Brentuximab vedotin plus chemotherapy for CD30+ T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how well a combination drug treatment (brentuximab vedotin plus chemotherapy) works for patients with rare T-cell lymphomas in real-world clinical practice in Spain. It focuses on patients receiving this as their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a CD30-positive peripheral T-cell lymphoma (such as anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, or related subtypes)
- You are 18 years of age or older
- You received brentuximab vedotin plus CHP chemotherapy as your very first lymphoma treatment
- Your treatment occurred between January 2019 and September 2024
- You have not received any other treatment for your lymphoma before this combination
- You did not receive this drug combination as part of a separate clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, chidamide and brentuximab vedotin, for people with a type of T-cell lymphoma that has the CD30 protein. It is for patients who are older or not healthy enough for standard chemotherapy, and whose cancer has come back or not responded to previous treatment.
This trial tests a new combination of targeted antibody-drug (brentuximab vedotin) plus standard chemotherapy (R-CHP) for people with a specific type of aggressive lymphoma that has a virus (EBV) in the tumor cells. The goal is to see if this combination works better than standard treatment.
This trial is a survey study that looks at how brentuximab vedotin is used in children with Hodgkin lymphoma. It focuses on people whose tumor is CD30-positive and who have not had prior treatment, to see how the drug fits with a standard chemotherapy plan (AVD).
This trial studies whether brentuximab vedotin given in the “second-line” setting can help people with relapsed or hard-to-treat classic Hodgkin lymphoma get ready for an autologous (your own cells) stem cell transplant. It’s specifically for tumors that test positive for CD30, and it checks safety and how well treatment works before transplant.
This trial tests a combination of two drugs for people with a specific type of skin lymphoma. Brentuximab vedotin targets a protein called CD30 on lymphoma cells, and lisaftoclax helps destroy those cells. The goal is to see if this combination is safe and effective.
This trial tests whether the drug brentuximab vedotin can help prevent lymphoma from coming back after a stem cell transplant. It is for people with a specific type of skin lymphoma called mycosis fungoides.
Hear when a new CD30-Positive Peripheral T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.